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Abstract 
Purpose. Group B Coxsackieviruses (CVB) include 6 serotypes (B1-6) responsible 
for a wide range of clinical diseases. Since no recent seroepidemiologic data are 
available in Italy, the study aim was to investigate CVB seroprevalence in a wide 
Italian population. 
Methods. The study retrospectively included 2,459 subjects referring to a large 
academic hospital in Rome (Italy) in the period 2004-2016. Seroprevalence rates and 
neutralizing antibodies (nAb) titers were evaluated in relation to years of observation 
and subjects’ characteristics. 
Results. Positivity for at least one serotype was detected in 69.1% of individuals. 
Overall, the prevalent serotype was B4, followed by B3 (33.3%), B5 (26.2%), B1 
(12.7%), B2 (11.0%), and B6 (1.7%). For B2, a significant decrease in seroprevalence 
over years was observed. Positivity to at least one virus was 25.2% in children aged 0-
2 years, but significantly increased in pre-school (3-5 yr) (50.3%) and school (6-10 yr) 
children (70.4%). Higher nAb responses for B3 and B4 were observed in children 
aged 3-5 years. 
Conclusion. A high overall CVB prevalence was found. Type-specific variations in 
prevalence over time probably reflect the fluctuations in circulation typical of 
Enteroviruses. Children are at greater risk for CVB infection given the high number of 
seronegative subjects aged 0-10 years. 
Keywords. Coxsackievirus, seroprevalence, neutralizing antibodies, epidemiology, 
Enterovirus. 
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Introduction 
Group B Coxsackieviruses (CVB) are members of the family Picornaviridae, genus 
Enterovirus, species Enterovirus B, including 6 serotypes (B1-6). The acute infection, 
generally asymptomatic, is responsible for a wide range of diseases in children as well 
as in adults. Clinical presentations can be mild (flu-like or febrile symptoms, hand, 
foot and mouth disease1) or severe (meningitis2, acute flaccid paralysis3, pancreatitis4, 
acute myocarditis and pericarditis5,6). CVB seem also able to establish persistent 
infection in heart7 and pancreatic islets8, and the reactivation could be linked to 
disease development6. Interestingly, CVB infection has been proposed as 
immunologic trigger for the development of insulin-dependent diabetes9,10, although 
currently there are no confirmed causal evidences. In a recent study, however, a 
vaccine for B1 serotype conferred protection against virus-induced type 1 diabetes in 
a mouse model11.  
CVB diffusion is ubiquitous and B1-5 serotypes display different circulation over the 
years12-15. Changes in circulating types may develop as large-scale outbreaks, as 
observed in 2007-2009 with a B1 epidemic that caused fatal cases of neonatal 
myocarditis in the USA and Korea16,17. Essentially, CVB reflect the epidemic 
potential of Enteroviruses, pointing out the importance of surveillance. 
Despite the widespread diffusion and the serious clinical presentations of CVB, 
seroepidemiologic data are limited worldwide. The last Italian work on this topic was 
published nearly 30 years ago18. To fill this gap, a retrospective analysis on CVB 
seroprevalence was performed on 2,459 individuals over a 13-year-long period. 
Neutralizing antibodies (nAb) titers were evaluated for all six serotypes, giving an 
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insight into local CVB prevalence trends and investigating the immune status of 
different age-groups. 
Materials and Methods 
Patients and specimens. A total of 2,459 subjects hospitalized or visited at Umberto I 
University Hospital (Rome, Italy) from 2004 to 2016 were retrospectively included in 
the study. Information about age was available for 2,114 individuals. Patients’ sera 
were routinely analyzed for suspected CVB infection following a physician’s request. 
Clinical information was available for 486 patients, who showed one or more of the 
following symptoms: chest pain, cardiopathy, endocarditis, pericarditis, myocarditis, 
pericardial effusion, encephalitis, meningitis, pancreatitis, rash, fever, 
lymphadenopathy, arthralgia, gastroenteritis, or pneumonia.  
Procedures performed in the study were in accordance with the ethical standards of 
the institutional and national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards. For this type of 
retrospective study, formal consent is not required. 
Micro-neutralization assay. Samples were screened with a micro-neutralization 
assay to detect neutralizing antibodies (nAb) against all six CVB. The serotypes were 
provided by the Virology Unit at Cisanello University Hospital (Pisa, Italy). After 
inactivation at 56°C for 30 minutes, sera were twofold serially diluted from 1:8 to 
1:512 and tested in duplicate in a 96-well plate. Fifty μl of B1-B6 virus with 100 
TCID50 were mixed with 50 μl of each serum dilution and incubated at 37°C for 1 
hour in 5% CO2. To each well 100 µl of KB cell suspension (human epithelial 
carcinoma) (3∙105 cells/ml) were added and the plate was incubated at 37°C in 5% 
CO2. Cell control and virus back titration were included, and a titration was performed 
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to determine the virus titer. The presence of cytopathogenicity was evaluated after 4 
days. The nAb titer was expressed as the geometric mean of the highest serum 
dilutions able to inhibit the viral cytopathic effect. Titers greater than or equal to 1:32 
were considered positive. For titers higher than 1:512, the test was repeated adding 
further serum dilutions.  
For 319 patients, a second serum sample was collected and sent to the laboratory after 
10-15 days. Both the first and the second sample were then screened by micro-
neutralization assay. The nAb geometric mean of the titers obtained for the 2 samples 
was used for the analysis. Patients with a 4-fold increase of nAb titers in the second 
sample were diagnosed with acute CVB infection and were not included in the study. 
Statistical analysis. Seroprevalence and 95% confidence intervals (CI) according to 
Wilson method were calculated. Chi-squared and Mann–Whitney tests were used to 
analyze the differences in seroprevalence and nAb titers between groups, respectively. 
The trends of seroprevalence over time were analyzed using the chi-squared test for 
trend. Statistical tests were conducted two-sided at a significance level of 0.05 using 
GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla California 
USA).  
Results 
Subjects’ characteristics. This study included 2,459 individuals (males: 54.7%, 
1,346/2,459) referring to a large academic hospital in Rome from 2004 to 2016. The 
2,114 subjects with available information on age were divided into 11 age-groups. 
Age ranged from 1 month after birth to 97 years (mean age: 32.3±25.2 years).  
Coxsackievirus B1-6 seroprevalence. Positivity for at least one serotype was found 
in 69.1% of individuals (95% CI:67.2-70.9). Considering the whole 13-years-long 
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period of study, the prevalent serotype was B4 (45.2%, 95% CI: 43.3-47.2), followed 
by B3 (33.4%, 95% CI: 31.5-35.2) and B5 (26.2%, 95% CI: 24.5-27.9). Lower 
seroprevalence was observed respectively for B1 (12.7%, 95% CI: 11.4-14.1), B2 
(11.0%, 95% CI: 9.8-12.3) and B6 (1.7%, 95% CI: 1.3-2.3) (Figure 1). 
Significantly higher nAb levels were found for B3 and B4 compared to all other 
viruses (p<0.0001), for B5 respect to B1 and B6 (p<0.0001), and for B2 compared to 
B6 (p<0.05) (data not shown).  
B1-5 serotypes exhibited remarkable changes in positivity rates over time (Figure 2). 
The greatest variation was observed for B2 seroprevalence, which was the highest in 
2004 (64.8%, 95% CI: 54.4-73.9) but significantly decreased in 2005 and 2006 
(50.5%, 95% CI: 40.9-60.1, and 31.2%, 95% CI: 23.3-40.4), settling at low rates from 
2007 to 2016 (range: 3.3%-8.1%) (p<0.0001). B1, B3, B4 and B5 instead showed a 
cyclical pattern, with periods of lower positivity rates followed by 1-3 years of 
increased seroprevalence. B3, B4 and B5 displayed a significant decrease in 
seroprevalence over years (p<0.05). A specific trend was not evidenced for B6, due to 
its low seroprevalence never exceeding 5%.  
The fluctuating seroprevalence patterns over years seem to be partially reflected in 
nAb titers’ distributions (Figure 2). NAb levels for B2 were higher in 2004-2006 but 
strongly decreased in the following years (p<0.05), similarly to B2 seroprevalence. B3 
titers were significantly higher in 2014 than most of the other years (p<0.05), in 
correspondence of a seroprevalence peak. For B4 and B5 significantly lower levels 
were observed both for titers (p<0.05) and seroprevalence in 2015. Differently, higher 
titer values were found for B5 in 2005 (p<0.05), but without an increase in 
seroprevalence.  
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Sex-related seroprevalence. Positivity rates stratified by sex reflected the general 
B1-6 seroprevalence, but the percentage of seropositivity was higher in females than 
in males (Figure 3a). This difference was significant for B2 and B3 (p<0.05). The nAb 
levels were higher but not significant in females than in males (Figure 3b). 
Age-related seroprevalence. Positivity for at least one serotype was lowest in 
toddlers aged 0-2 years (25.2%; 95% CI: 20.4-30.7), but strongly increased in pre-
school (3-5 years) (50.3%; 95% CI: 42.6-58.0) and school (6-10 years) children 
(70.4%; 95% CI: 63.1-76.8) (p<0.0001) (Figure 4). Seropositivity remained constantly 
high in the following groups, with the highest value observed at 41-50 years (85.9%; 
95% CI: 80.9-89.8), but decreased to 61.0% at 81-90 years (95% CI: 48.3-72.4). The 
number of individuals with multiple positivity also increased with age. In the 0-2 
years group, nAb were directed against one serotype in 68.7% (95% CI: 56.8-78.5) of 
seropositive children, and against 2 and 3 serotypes respectively in 16.4% (95% CI: 
9.4-27.1) and 7.5% (95% CI: 3.2-16.3) (Figure 4). At 3-5 years, 35.0% (95% CI: 25.5-
45.9) of seropositive children had nAb for 2 viruses. The 41-50 years-old group 
showed the highest percentage of positivity for 3 viruses (22.4%, 95% CI: 17.2-28.6). 
Positivity to 4 and 5 viruses was observed in less than 6% of seropositive individuals, 
and positivity to all CVB was rare (less than 1.0%). 
The age-related positivity increase is significant also in analyzing B1-B5 specific 
seroprevalence. Interestingly, nAb titers distributions did not always reflect this trend 
(Figure 5). The 0-2 year group showed the lowest positivity rates, comprised between 
10% and 12% for B3, B4 and B5. In the following age-groups, B4 had higher rates of 
seroprevalence compared to all other viruses, with a marked increase passing from 
preschoolers (25.2%, 95% CI: 19.1-32.4) to school children (40.2%, 95% CI: 33.1-
47.8), and two peaks at 41-50 and 71-80 years. However, B4 nAb titers were higher in 
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younger subjects, with a significant difference at 3-5 years with respect to age-groups 
over 10 years-old (p<0.05), and lower at 71-80 years compared to groups under 60 
years (p<0.05). Only B4 maintained high seroprevalence in older ages. B3 and B5 
showed a similar pattern with two peaks of increasing prevalence at 11-20 and 41-50 
years, and a decrease in individuals older than 50 years. B3 nAb levels were 
significantly higher in children aged 3-5 years (p<0.02) and lower starting from 61 
years (p<0.05). For B5 a significative difference was evidenced comparing nAb titers 
of the first 4 groups (0-20 years) with the 51-60 years group (p<0.03), and titers of the 
first 2 groups (0-5 years) with the 61-70 and 71-80 year-old groups (p<0.05). B1 and 
B2 seroprevalence rates were always under 21% but peaked at different age-groups 
(6-10 and 41-50 years, respectively). No significant difference was observed in terms 
of nAb titers for these two serotypes. As far as B6 is concerned, a modest 
seroprevalence increase was observed at 41-50 and 51-60 years (4.2% and 4.6%) (data 
not shown). 
Discussion 
Clinical presentations of CVB are remarkably different and present various degrees of 
severity, from asymptomatic infection to meningitis and chronic inflammation of the 
heart and pancreas. No single serotype is linked to a specific disease. In addition, 
epidemiological and animal studies suggest that CVB could have a role in type 1 
diabetes; to verify this hypothesis, the development of a human vaccine was recently 
announced19.  
In this context, the measurement of pre-existing immunity is important to deduce 
prevalence and to identify susceptible populations. Few recent studies focused on 
CVB seroprevalence in Europe20, 21, and the last Italian work about this topic dates to 
 This article is protected by copyright. All rights reserved. 
A
cc
ep
te
d 
A
rt
ic
le
 
199118. In this work a retrospective serologic study conducted in 2,459 individuals in 
Rome during a 13-year-long period is reported. Seroprevalence rates and nAb titers 
were analyzed in relation to gender and age of the subjects and to the year of 
observation, with the purpose of investigating the level of past exposure to the 6 CVB 
types. 
Seropositivity for at least one virus was identified in 69.1% of samples, demonstrating 
the widespread diffusion of CVB infection in the study population. B4 was the most 
prevalent virus, with nearly half of the individuals having experienced the infection, 
followed by B3, B5, B1 and B2, while B6 nAb were detected sporadically. In 1991 in 
the area of Bari (South Italy), seroprevalence in children was higher for B1, B2 and 
B518. A European study conducted in 2001-2005 showed that B1-6 seroprevalence 
and ranking differed depending on the subjects’ country, but B1 and B6 were the least 
represented CVB, similarly to our findings21. These differences are not surprising, 
since Enterovirus diffusion is characterized by temporal and geographical variation, 
preventing the confrontation of data between different years and location22. As a 
confirmation of this, the positivity values were not steady, but rather changed over 
years. In fact, B1, B3, B4 and B5 seroprevalence patterns underwent cyclical 
variations that could reflect differences in circulation, consistently with CVB 
epidemiology and with several surveillance works12-15,23,24. The most noticeable 
difference was observed for B2 seroprevalence, which decreased from 65% in 2004 to 
levels lower than 8.5% starting from 2007, being replaced by B4 as seroprevalent 
type. To our knowledge, a decline in B2 seroprevalence in 2004-2007 is not 
documented elsewhere. This trend could reflect a period of wider circulation during 
and/or prior to 2004, followed by a decrease in the number of infections. An increase 
in B2 detection was observed in a surveillance study in 2004 in France23, and B2 had 
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the highest seroprevalence in individuals from Sweden and Greece in 2001-200521. 
Unfortunately, recent data about B2 surveillance or prevalence in Italy are not 
available. The median age of patients was higher in 2004 (data not shown), so the 
higher seroprevalence observed for B2 in that year could be attributed to a different 
age distribution of population. Moreover, it cannot be excluded that the decrease in B2 
nAb detection was due to the circulation of a “new” strain with different antigenic 
properties and able to elicit a different nAb response.  
The 6 serotypes determined nAb production with different intensities. B3 and B4 
stimulated the strongest responses, while nAb levels were lower for B1 and B6. 
Similar results were reported by Oikairinen et al.21. In another work analyzing B3 and 
B5 prevalence, nAb GMT of B3 was higher than B525. Repeated immune stimulations 
due to the wide diffusion of B3 and B4 could contribute to maintaining high levels of 
nAb in subjects who previously experienced the infection. On the contrary, a low 
production of B1 and B6 nAb could reflect their lower diffusion or their ability to 
escape the immune response.  
Host factors also influence nAb levels. In this study higher values were detected in 
females, and similar data were obtained for B4-IgG in children26. Females had also 
higher seroprevalence values, and the difference was significant for B2 and B3. 
However, other works did not report significant gender-specific differences in CVB 
positivity18,25,27. Increasing number of evidences suggest that female subjects produce 
a more intense immune response during viral infections, maintaining it also after the 
pathogen’s clearance28. Mechanisms involved in sex-related difference in immunity 
are mostly unknown, but our results probably reflect this phenomenon. 
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The study clearly evidences that positivity for at least one serotype increases with age, 
together with the number of individuals having experienced infection with more than 
one virus. These findings are consistent with the observations of other 
groups18,21,25,27,29. Preschoolers are the subjects at higher risk of infection: about 75% 
of children aged 0-2 years and 50% of children aged 3-5 years had never experienced 
CVB infection. Since no vaccine is available for CVB, nurseries and schools probably 
have an important role in the transmission of infection in children. In addition, a 
higher nAb production for B3 and B4 was observed in children aged 3-5 years. The 
same observation was reported for B3 in a Chinese population25. A stronger antibody 
response is probably stimulated by the high viral circulation in this age-group or 
reflects a recent primary infection. On the contrary, B4, B3 and B5 nAb levels were 
lower in older age-groups, compatibly with a condition of reduced adaptive immune 
function in these subjects30. 
In conclusion, the great number of samples included in the analysis allowed the 
gathering of comprehensive information on CVB epidemiology, highlighting sero-
specific seroprevalence variations over time and in different age-groups. Serologic 
data are valuable to assess the risk of outbreaks and for the development of future 
immunization programs. Limitations of this work are the lack of clinical information 
for the whole population and the fact that the study cannot be considered as a sero-
survey of healthy subjects. Moreover, the analysis is not based on a multi-center 
experience, therefore our data could not represent the seroprevalence in the Italian 
population. However, considering that the results derived from one of the 3 largest 
public and academic hospital in Italy, and the lack of studies on CVB seroprevalence 
in Italy, this work provides a well characterized seroepidemiologic insight and 
underlines the need for a continuous monitoring of CVB epidemiology. 
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Figure legends 
Fig. 1 CVB seroprevalence from 2004 to 2016 
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Fig. 2 B1-6 seroprevalence trends (dashed lines) and nAb titers’ distributions (box 
plots) for each year of observation (2004/2016). Box plots show the minimum, first 
quartile, median, third quartile and maximum logarithmic titer levels 
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Fig. 3 NAb titers’ distributions (a) and seroprevalence (b) of CVB in male and female 
subjects (*p<0.05). The box plots show the minimum, first quartile, median, third 
quartile and maximum logarithmic titer levels 
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Fig. 4 Proportions of individuals seropositive to one or more CVB classified for age-
group 
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Fig. 5 B1-5 seroprevalence trends (dashed lines) and nAb titers’ distributions (box 
plots) observed in age-groups. Box plots show the minimum, first quartile, median, 
third quartile and maximum logarithmic titer levels 
 
